Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Assets (2016 - 2026)

Anika Therapeutics has reported Assets over the past 17 years, most recently at $179.4 million for Q1 2026.

  • Quarterly Assets fell 5.89% to $179.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $179.4 million through Mar 2026, down 5.89% year-over-year, with the annual reading at $190.3 million for FY2025, 6.15% down from the prior year.
  • Assets was $179.4 million for Q1 2026 at Anika Therapeutics, down from $190.3 million in the prior quarter.
  • Over five years, Assets peaked at $354.1 million in Q2 2022 and troughed at $179.4 million in Q1 2026.
  • The 5-year median for Assets is $263.7 million (2024), against an average of $268.1 million.
  • Year-over-year, Assets grew 0.46% in 2022 and then dropped 29.48% in 2024.
  • A 5-year view of Assets shows it stood at $349.1 million in 2022, then decreased by 22.48% to $270.6 million in 2023, then dropped by 25.09% to $202.7 million in 2024, then decreased by 6.15% to $190.3 million in 2025, then decreased by 5.72% to $179.4 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Assets are $179.4 million (Q1 2026), $190.3 million (Q4 2025), and $189.4 million (Q3 2025).